Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor (G‑CSF) presented as an injectable solution (lyophilized powder for reconstitution) for intravenous and subcutaneous use. It is employed to treat chemotherapy‑induced neutropenia, neutropenia following bone marrow transplantation, severe chronic neutropenia, and to mobilize peripheral blood stem cells for collection.

GNH USA supplies Neupogen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is a granulocyte colony‑stimulating factor used to manage neutropenia in several clinical settings.

- Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk. - Neutropenia following bone marrow transplantation: accelerates neutrophil recovery post‑transplant. - Severe chronic neutropenia: raises absolute neutrophil counts in patients with persistent low levels. - Peripheral blood stem cell mobilization for collection: enhances stem cell yield for autologous transplantation.

Neupogen may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bone pain: discomfort in the limbs or back. - Injection site reactions: redness, swelling, or tenderness. - Fever: mild to moderate temperature elevation. - Headache: transient cranial discomfort. - Fatigue: general feeling of tiredness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring urgent care. - Acute respiratory distress syndrome: severe breathing difficulty. - Severe allergic reactions: anaphylaxis with rash, swelling, or airway compromise. - Capillary leak syndrome: hypotension and edema. - Leukocytosis: excessively high white blood cell counts. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Neupogen, clinicians should consider several safety measures.

- Monitor complete blood count: adjust therapy based on neutrophil levels. - Assess splenomegaly: avoid use in patients with known enlarged spleen. - Use caution in sickle cell disease or other hematologic disorders. - Avoid concurrent use with other myeloid growth factors unless directed. - Consider renal or hepatic impairment: dose may need modification. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neupogen can interact with other medicines, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Concurrent use with other granulocyte colony‑stimulating factors: risk of excessive neutrophil proliferation. - Co‑administration with high‑dose corticosteroids: may blunt filgrastim response. - Use with investigational agents affecting bone marrow: unpredictable hematologic effects.

Moderate Interactions (Monitor Closely): - Antibiotics: may mask signs of infection while neutrophils rise. - Anticoagulants: monitor bleeding if thrombocytopenia coexists. - Immunosuppressants: increased vigilance for opportunistic infections.